Results 241 to 250 of about 693,260 (339)

AI in Neurology: Everything, Everywhere, all at Once PART 2: Speech, Sentience, Scruples, and Service

Annals of Neurology, EarlyView.
Artificial intelligence (AI) applications are finding use in real‐world neurological settings. Whereas part 1 of this 3‐part review series focused on the birth of AI and its foundational principles, this part 2 review shifts gears to explore more practical aspects of neurological care.
Matthew Rizzo
wiley   +1 more source

Population-based spectral characteristics of normal interictal scalp EEG inform diagnosis and treatment planning in focal epilepsy. [PDF]

Sci Rep
Wagh N, Duque-Lopez A, Joseph B, Berry B, Jehi L, Crepeau D, Barnard L, Gogineni V, Brinkmann BH, Jones DT, Worrell G, Varatharajah Y.   +11 more
europepmc   +1 more source

A Study of Epilepsy in its Clinical, Social, and Genetic Aspects [PDF]

, 1951
Mortimer Ostow
openalex   +1 more source

AI in Neurology: Everything, Everywhere, All at Once Part 3: Surveillance, Synthesis, Simulation, and Systems

Annals of Neurology, EarlyView.
This final part 3 review builds on the practical applications discussed in part 2 and explores how artificial intelligence (AI) is transforming data management, neurological education, and neurological care across large healthcare networks and datasets. The review also highlights AI's role in real‐world and synthetic data, digital twins, and innovative
Matthew Rizzo
wiley   +1 more source

The impact of nursing intervention on the care burden experienced by mothers of children with epilepsy: a family-centered empowerment model. [PDF]

BMC Nurs
Abdelgawad SME, Radwan SA, Elsayed ZEH.
europepmc   +1 more source

RAPIDLY PROGRESSIVE CEREBRAL DEGENERATION (SUBACUTE VASCULAR ENCEPHALOPATHY) WITH MENTAL DISORDER, FOCAL DISTURBANCES, AND MYOCLONIC EPILEPSY [PDF]

, 1954
D. P. Jones, S. Nevin
openalex   +1 more source

Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in relapsing and progressive forms of multiple sclerosis (MS).
Bruce A.C. Cree, Mark S. Freedman, Michael Gold, Kimberly Pfleeger, Brittany Schwefel, Annette Wundes, Adam Ziemann   +6 more
wiley   +1 more source

Clinical characterization and management of persons with comorbid epilepsy and depression: an expert opinion paper. [PDF]

Front Pharmacol
Sampogna G, Brugnoli R, Didato G, Elia M, Ferlazzo E, Serafini G, Vatti G, Volpe U, Villani F, Sani G.   +9 more
europepmc   +1 more source

STUDIES IN TRAUMATIC EPILEPSY: 3. VISUAL FITS [PDF]

, 1955
W. R. Russell, C. W. M. Whitty
openalex   +1 more source

Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder

Annals of Neurology, EarlyView.
Objective To determine the impact of dopamine deficiency and isolated rapid eye movement (REM) sleep behavior disorder (iRBD) on cognitive performance in early neuronal α‐synuclein disease (NSD) with hyposmia but without motor disability. Methods Using Parkinson's Progression Markers Initiative baseline data, cognitive performance was assessed with a ...
Daniel Weintraub, Anuprita R. Nair, Ryan Kurth, Michael C. Brumm, Christine Kohnen, Michele K. York, Roseanne D. Dobkin, Kenneth Marek, Caroline Tanner, Tanya Simuni, Andrew Siderowf, Douglas Galasko, Lana M. Chahine, Christopher Coffey, Kalpana Merchant, Kathleen L. Poston, Tatiana Foroud, Brit Mollenhauer, Ethan G. Brown, Karl Kieburtz, Mark Frasier, Sohini Chowdhury, Roy N. Alcalay, Aleksandar Videnovic, The Parkinson's Progression Markers Initiative   +24 more
wiley   +1 more source